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1. Introduction
There is consensus among investigators studying Autism Spectrum Disorders (ASD) that
the etiological basis involves environmental factors acting on the genetic susceptibility of the
individual [1-5]. Over 100 candidate genes that may contribute to ASD susceptibility have
been identified, and numerous environmental “triggers” have been suggested. Yet, the
cause of ASD eludes clear definition and most likely is, as in most diseases, multi-factorial.
However, several common immunological themes emerge from clinical and experimental
studies of ASD, including persistent neuroinflammation, immune dysregulation, or autoim‐
mune manifestations in many autistic children. Thus, in addition to genetic and environ‐
mental factors, there is compelling evidence that immune factors also play a role in ASD.
Abnormalities consistent with immune dysregulation, including abnormal or skewed T
helper (Th) cell subsets and cytokine profiles, decreased lymphocyte numbers, decreased T
cell mitogen responses, and an imbalance of serum immunoglobulin levels have been re‐
ported in children with ASD [6-11].
Recent results of transcriptomic analysis of autistic brains [5] provides strong evidence sup‐
porting a gene-environment etiology for ASD. These authors demonstrated consistent differ‐
ences in transcriptome organization in the cerebral cortex of autistic and normal brains, and
identified two discrete modules of co-expressed genes associated with autism. The first, a
neuronal module of 209 genes, was enriched for known autism susceptibility genes, and the
second module of 235 genes was enriched for immune genes and glial markers. Gene enrich‐
ment analysis showed that genes in the neuronal module were downregulated and enriched
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for gene ontology categories related to synaptic function, whereas the genes in the immune-
glial module were upregulated, and showed enrichment for gene ontology categories impli‐
cated in immune and inflammatory responses. The finding of a genetic association for the
neuronal module genes, but a non-genetic association for the immune-glial module genes
strengthens the gene-environment etiology for ASD.
Compelling clinical data demonstrate that children of mothers exposed to certain infectious
organisms during pregnancy have significantly higher frequencies of neurological disorders
[12-21], including schizophrenia and ASD, the etiology of which have been linked to activa‐
tion of the maternal inflammatory/immune responses (reviewed in [9, 22]). Rodent studies
in which the maternal immune system is activated during pregnancy replicate these clinical
findings, and provide validated mouse models of ASD [14, 15, 19, 23-33]. We have used a
well-characterized prenatal mouse model to investigate questions related to the influence of
maternal immune stimulation during pregnancy as an environmental risk factor that affects
development of the brain and immune system in the offspring.
Injection of pregnant dams with polyclonal immune stimuli, [e.g., polyinosinic-polycytidylic
acid (poly(I:C), lipopolysaccharide (LPS)] or direct injection of the pro-inflammatory cyto‐
kines these polyclonal stimuli induce (e.g., IL-1, IL-2, IL-6) cause immune dysregulation and
behavioral abnormalities in their offspring in comparison to the offspring of pregnant dams
given a control [i.e., Phosphate Buffered Saline (PBS)] injection [30, 34-39]. The underlying
mechanisms that mediate these abnormalities have not been clearly defined, and are the fo‐
cus of ongoing studies by us and others. A unique and powerful advantage of this model is
the ability to examine subjects for the initiation and persistence of effects and mechanisms
over a continuum of time and development from the earliest embryonic stages through the
neonatal period and into adulthood.
While it is impossible for any animal model to completely replicate a human condition as
complex as ASD, the mouse model of maternal immune stimulation with poly(I:C) has been
recognized as an excellent prenatal model for numerous reasons presented in recent reviews
by Meyer and Feldon [40] and Patterson [41]. These include (i) face validity (resemblance to
the human symptoms) (ii) construct validity (similarity to the underlying causes of the dis‐
ease) and (iii) predictive validity (expected responses to treatments that are effective in the
human disease) [42]. Thus, offspring from poly(I:C)-injected dams exhibit behavioral
anomalies reminiscent of those seen in autistic and schizophrenic individuals. In addition to
their behavioral abnormalities, our studies show that as a result of in utero exposure to
products of maternal immune stimulation these offspring also exhibit a “pro-inflammatory”
phenotype that confers a vulnerability to develop immune-mediated pathology after birth
and into adulthood [43-45].
In this regard, the results obtained from our investigation of the poly(I:C) mouse model
have provided the scientific rationale for an ongoing translational research project to deter‐
mine if similar molecular pathogenic mechanisms are involved in a cohort of ASD children
who also exhibit diagnostic evidence of immune dysregulation [46]. Using DNA obtained
from the Autism Genetic Resource Exchange (AGRE) database, we initiated a parallel study
to determine if there were polymorphisms in selected maternal cytokine genes that occurred
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more frequently in mothers of these autistic children. Our results show that mothers of au‐
tistic children in this cohort have significant increases in pro-inflammatory cytokine gene
polymorphisms, thereby conferring the genetic capability to respond more vigorously to im‐
mune stimulation by producing the types and amounts of cytokines that promote inflamma‐
tory reactions. Thus, results obtained from our investigation of the experimental prenatal
mouse model of maternal immune stimulation during pregnancy have already shown bio‐
logical relevance in humans.
Th cell Type Surface Markers Signal Pathways Transcription
Factor
Inducing Cytokines Cytokines
produced
Th1 CD4; Tim-3 STAT1 T-bet IL-12 IFN-γ, IL-2
Th2 CD4; T1/ST2 STAT3 GATA3 IL-4 IL-4,5,10,13
Th17 Not yet defined STAT3 RORγt
IL-1, IL-6 TNF-α
TGF-β IL-1,6,17,21,22
Treg CD4; CD25hi FoxP3 FoxP3 TGF-β IL-10, TGF-β
Table 1. Properties of T helper (Th) cell subsets
The hypothesis we are investigating in the prenatal mouse model is that maternal immune
stimulation during pregnancy acts as a “first hit” that alters the developing immune system
in ways that result in more robust pro-inflammatory immune responses by offspring upon
subsequent (i.e. second hit) postnatal immune stimulation. Moreover, such fetal program‐
ming occurs in elements of both the innate and adaptive immune systems. Therefore, our
experiments investigate how maternal immune stimulation during pregnancy influences the
development and function of myeloid and lymphoid compartments of the immune system
beginning at the level of the progenitor cells, and progressing to functional outcomes in neo‐
nates and adult offspring. In the myeloid compartment, we are focusing on the functions of
Antigen Presenting Cells (APC), and on those innate immune elements that mediate acute
inflammatory responses. With respect to the adaptive immune system, we are focusing on
pro-inflammatory T helper (Th) cell subsets (Th1 and Th17) and anti-inflammatory Th cell
subsets [T regulatory (Treg) cells and Th2 cells]. To do this, we are using several well-charac‐
terized model systems to document the pro-inflammatory nature of the offspring of
poly(I:C)-injected vs. PBS-injected pregnant dams. The results of these studies are forming a
solid foundation to investigate how the pro-inflammatory phenotype exhibited by these off‐
spring also contributes to the etiology and neuroinflammation associated with ASD.
Th cell subsets are induced by different cytokines, use different cell signaling pathways, and
produce unique cytokine profiles mediated by cytokine-specific transcription factors (Table
1). Th17 and Treg cells are dependent on cytokines for their development, maintenance, and
function, and have been implicated in modulating the incidence and/or progression of vari‐
ous inflammatory and autoimmune phenomena, including rheumatoid arthritis (RA) [47],
Experimental Autoimmune Encephalomyelitis (EAE) [48-50], Inflammatory Bowel Disease
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(IBD) [51-53], diabetes [54, 55], and atherosclerosis [56, 57]. Thus far, however, little is
known about the involvement of proinflammatory Th1 and Th17 cells in autism, and how
Th cell subsets interact with microglial APC in the brain [58].
Figure 1. Prenatal models of maternal immune stimulation during pregnancy
2. Prenatal models of immune stimulation using poly(I:C)
In the prenatal model of maternal immune stimulation with poly(I:C) (Figure 1), C57BL/6
(B6) females and males are mated, and appearance of a vaginal plug is considered day zero
of gestation (E0). At E12, pregnant females are given a single i.p. injection of poly(I:C) or
PBS alone as a control. Sera and amniotic fluids are harvested, and stored at -80oC prior to
measurement of cytokine levels by Luminex® bead-based multiplex assay [59] that meas‐
ures up to 32 individual cytokines. In vitro and in vivo analyses are also performed on the
neonatal and adult offspring of these poly(I:C)-injected and PBS-injected pregnant dams to
assess the phenotype and function of their innate and adaptive immune system compo‐
nents. As also shown in Figure 1, we mate females that are immunologically naïve (i.e., non-
immune), as well as females that possess immunological memory (i.e., immune) with
immunologically naïve males. The phenotype of the offspring from these mating schemes
reflects the immune status of the of the pregnant dams, and the nature of the prenatal stimu‐
lus. Our results demonstrate that offspring of both non-immune and immune poly(I:C)-in‐
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jected dams exhibit a pro-inflammatory phenotype in comparison to offspring of PBS-
injected dams. In addition, however, T helper (Th) cells from offspring of immune poly(I:C)-
injected dams show a unique ability to preferentially differentiate to become pro-
inflammatory Th17 cells.
Figures 2A and 2B show the significant increases in IL-6 at 2hr and 16hr after poly(I:C) injec‐
tion, and similar differences were also seen in levels of IL-1β, IL-12, TNF-α, and GM-CSF in
these samples [45, 60].
Figure 2. IL-6 levels in sera and amniotic fluids from B6 pregnant dams. Samples collected 2hrs after injection of
poly(I:C) or PBS were tested for IL-6 in sera (A) and amniotic fluids (B) using Luminex bead-based multiplex assay. Data
show mean ± SEM. (N=3-8; **p<0.01 using Tukey’s HSD test )
In addition to testing sera and amniotic fluids from pregnant dams, we also analyze pheno‐
typic and functional characteristics of lymphoid cells from offspring. To avoid bias due to
“litter effects” [61], the number of subjects examined in our experiments not only reflects off‐
spring within a litter, but also offspring from multiple dams, so that the “N” in our studies
considers both the number of dams, as well as the number of offspring.
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Use of immunologically naïve pregnant dams: Immunologically naïve mice are used by most in‐
vestigators in the standard prenatal model of immune stimulation during pregnancy. These
pregnant dams are injected with poly(I:C) on embryonic day 12 (E12), and control pregnant
dams are injected with PBS. The embryos and offspring from these dams are then used ex‐
perimentally to determine the influence of maternal immune stimulation on prenatal devel‐
opment and postnatal function. Since this model was originally developed to investigate
neurodevelopmental disorders, such as schizophrenia and autism, a majority of the studies
focus on the CNS and behavioral outcomes of offspring. These investigations have shown
that maternal immune stimulation during pregnancy with polyclonal stimuli [e.g., poly(I:C)
or LPS], infectious pathogens, or specific cytokines (e.g., IL-2 or IL-6) results in expression of
ASD-like behavioral manifestations, as well as structural or functional changes in cells in the
brain of the offspring [39-41, 61, 62].
However, in the prenatal models that use poly(I:C) as the immune stimulus, the type of
poly(I:C) (i.e., sodium or potassium salt), dose of poly(I:C) (2-20 mg/Kg), and time of in‐
jection  during  pregnancy  (E9  through  E18)  can  influence  some  of  the  parameters  that
have  been  examined  in  these  offspring,  including  open  field  exploration,  sensorimotor
gating (e.g.,  prepulse inhibition of the startle response),  and repetitive/perserverative be‐
havior ([63, 64].  It  is thought that poly(I:C)-induced maternal cytokines are primarily re‐
sponsible for the abnormalities  seen in offspring.  However,  downstream effects  induced
by these maternal cytokines or trans-placental stimulation of fetal tissues by poly(I:C) it‐
self have not been completely ruled out.
Use of  pregnant dams with immunological  memory:  In addition to the existing model  using
immunologically naïve dams, we also modified this mouse model of neurodevelopmental
disorders  by  using  dams that  possess  immunological  memory  prior  to  mating  [43,  44].
This experimental design more closely resembles the human scenario, where women pos‐
sess immunological memory resulting from immunizations and natural exposure to envi‐
ronmental antigens prior to pregnancy. Using dams with immunological memory yields a
more  robust  mouse  prenatal  model,  which revealed outcomes in  offspring that  may be
significant not only in the etiology and/or pathogenesis of schizophrenia and autism, but
also in other disorders  that  are  currently not  being considered by use of  these prenatal
mouse models.
In both of  these models,  we and others  have previously shown that  following injection
of poly(I:C), pregnant dams produce significantly higher levels of pro-inflammatory cyto‐
kines (e.g., IL-1, IL-6, IL-12, TNF-α, and GM-CSF) than PBS-injected dams in sera as well
as amniotic fluids. Most of the studies involving structural/chemical changes and behav‐
ioral  abnormalities  that  are  observed after  injection of  poly(I:C)  to  pregnant  dams have
been performed on adult  offspring from immunologically naïve pregnant dams.  Recent‐
ly,  Hsaio,  et  al.  [65]  observed alterations in the peripheral  immune system of  these off‐
spring.  Our results  indicate that  the adult  offspring of  immunologically naïve poly(I:C)-
injected  pregnant  dams  also  exhibit  a  more  robust  acute  inflammatory  response  after
injection of the TLR2 ligand, zymosan [45, 60].
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Figure 3. Enhanced production of Th17 cells in offspring poly(I:C)-injected (20mg/Kg) immune dams. Spleen
cells from 3wk old offspring of poly(I:C)- and PBS-injected dams were stimulated with 3ng/ml PMA and 100ng/ml ion‐
omycin for 16hr, the last 4hr of which were in the presence of 10ug/ml Brefeldin A to block cytokine secretion. Cells
were harvested, and stained with fluorochrome-conjugated mAbs to detect cell surface molecules and intracellular
cytokines by FACS analysis. The spleen cells analyzed in each of the panels were from offspring of PBS-injected immu‐
nologically naïve dams (A); offspring of poly(I:C)-injected immunologically naïve dams (B); offspring of PBS-injected
immune dams (C), and offspring of poly(I:C)-injected immune dams (D). Numbers in upper left quadrants are percen‐
tages of IL-17A+ (Th17) cells after gating on CD4+ cells. Results shown are representative of seven experiments com‐
paring 18 offspring from 12 different dams. Overall results of percentages of Th17 cells were: 15.1±7.8 in offspring
from immune poly(I:C)-injected dams vs. 0.8±0.5 in offspring from immune PBS-injected dams (p=0.05 using Tukey’s
HSD test )
The offspring of poly(I:C)-injected (vs. PBS-injected) pregnant dams who possess immuno‐
logical memory prior to pregnancy exhibit a unique pro-inflammatory phenotype in which
there is preferential development of Th17 lymphocytes after T cell activation (Figure 3) [43,
44]. This preferential Th17 cell development is not seen at all in offspring of immunological‐
ly naïve poly(I:C)-injected or PBS-injected pregnant dams. Given their role in immune-medi‐
ated disorders, it is likely that the potential to produce Th17 cells that we have discovered in
offspring of poly(I:C)-injected pregnant dams with immunological memory may also be an
important component in the neuroinflammatory pathogenesis of ASD-like changes that
have been observed in this prenatal mouse model. Thus, one hypothesis we have tested is
that the pro-inflammatory phenotype of offspring induced as a result of embryonic develop‐
ment in a pro-inflammatory cytokine environment in utero make them more susceptible
Pro-Inflammatory Phenotype Induced by Maternal Immune Stimulation During Pregnancy
http://dx.doi.org/10.5772/53990
119
(i.e., vulnerable) to develop immune-mediated pathology. Indeed, we have obtained com‐
pelling results from in vivo experiments in adult offspring that strongly support this possi‐
bility. Using a model of EAE, in which mice are injected with an encephalogenic-peptide,
Myelin Oligodendrocyte Glycoprotein peptide (MOG35-55), we found that adult offspring of
poly(I:C)-injected pregnant dams exhibited a significantly higher frequency and earlier on‐
set of clinical symptoms of EAE compared to offspring of PBS-injected pregnant dams [45,
60]. Our zymosan induced results and the EAE experiments are described in subsequent sec‐
tions of this chapter.
Maternal  vs.  fetal  sources  of  cytokines:  In  this  prenatal  model,  a  single  i.p.  injection  of
poly(I:C) (or control PBS) is given on gestational day 12 (E12). Convincing evidence from
this model by us and others [30, 43, 44, 61, 66-68] has shown that pro-inflammatory cyto‐
kines (IL-1, IL-6, IL-12, TNF-α, GM-CSF) produced as a result of maternal immune stim‐
ulation during pregnancy induce changes in the development of the immune system and
the brain of offspring that result in immunological and behavioral manifestations similar
to those seen in individuals with ASD. To what degree these changes are induced by cy‐
tokines  produced by  the  mother  or  fetus  has  not  been  fully  defined.  However,  our  re‐
sults  using  IL-6  knock-out  (KO)  dams  mated  with  wild  type  males  [44],  suggests  that
there is a fetal source for at least some of the cytokines detected in the amniotic fluid of
poly(I:C)-injected pregnant dams.
In  these  experiments,  our  results  from  mating  IL-6  knock-out  (KO)  B6  females  (IL-6-/-)
and wild-type (WT) B6 males (IL-6+/+) show that despite a maternal genetic deficiency for
IL-6 production, fetal components of the heterozygous IL-6+/- placenta are a source of this
cytokine (Figures 4 and 5), and heterozygous neonates can also produce IL-6 [44]. Using
similar  mating schemes in  this  prenatal  model,  however,  Hsiao,  et  al.  [66]  did not  find
IL-6 in amniotic  fluid of  poly(I:C)-injected pregnant  IL-6 KO B6 dams.  Our results  sug‐
gest that poly(I:C) (a TLR3 agonist) stimulates fetal placental tissues directly, and contrib‐
utes to the levels of IL-6 found in amniotic fluid. This is relevant to the interpretation of
data  about  the  source  of  IL-6  (as  well  as  other  cytokines)  found in  the  amniotic  fluids
and fetal tissues, such as the brain [9, 63, 69], and also because TLR3 is expressed in the
brain during fetal development [70].
Pregnant dams injected with Sickness behavior ratio N
PBS 1.00 ± 0.10 9
Poly(I:C) 0.40± 0.02* 21
Pregnant dams were analyzed for sickness behavior before and 2 and 24 hrs after poly(I:C) injection. All mice in a
group were analyzed by calculating a ratio, where each post injection sickness behavior score was divided by its pre-
injection score. The individual ratios were then used to calculate the means, standard errors, and significance values.
*p < 0.0001 (Tukey’s HSD test).
Table 2. Sickness behavior scores of immune poly(I:C)- and PBS- injected pregnant dams
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Figure 4. Source of cytokines in pregnant dams. Sera (N=6) and amniotic fluids (N=17) from IL-6 KO pregnant dams
were collected 24 hrs after injection of poly(I:C), and IL-6 levels determined by Luminex assay. (*p<0.0001 Tukey’s HSD
test).
Figure 5. Source of cytokines in offspring. Spleen cells from WT B6 (N=5) and spleen and placental cells from
poly(I:C)-injected IL-6 KO females (N=5) were cultured with/without PMA and Ionomycin (P/I). Supernatants were col‐
lected 24hrs later, and tested for the presence of IL-6 by Luminex assay. (*p<0.02; **p<0.01; Tukey’s HSD test)
Regardless of source, however, since in utero exposure to the products of maternal immune
stimulation during pregnancy appear to be part of the underlying mechanisms responsible for
the changes observed in offspring, it is important to be sure that the pregnant dam responds to
the immune stimulus if their offspring are used for experiments. We have addressed this issue
by monitoring locomotor activity in a novel environment in every pregnant dam before, and at
2hrs and 16hrs after injection as a reliable, non-invasive measure of response to poly(I:C). We
opted to use this method in lieu of more invasive procedures that would jeopardize pregnancy
in these dams and/or add a level of stress that could influence the cytokine levels and/or fetal
development. As shown in Figure 6 and Table 2, there is a consistent and dramatic decrease in
activity (indicative of “sickness behavior – [71-74]) in poly(I:C)-injected pregnant dams at 2hrs
post injection that is not seen in PBS-injected dams. Moreover, sickness behavior at 2hrs post
poly(I:C) injection correlates very nicely with the increased levels of pro-inflammatory cyto‐
kines seen at 2hrs in the sera and amniotic fluids of pregnant dams (Figure 2). Activity scores
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are measured in every pregnant dam, including those that are brought to term and give birth.
In this way, we are confident that the offspring used for subsequent in vivo and in vitro experi‐
ments to characterize phenotypic and functional immunological parameters were exposed in
utero to a pro-inflammatory cytokine milieu.
Figure 6. Sickness behavior scores in poly(I:C)-injected pregnant dams. Dams were tested before, and at 2hrs &
16hrs after poly(I:C) or PBS injection. Activity was monitored in a novel environment, and mice were given positive
scores for locomotion, rearing, grooming, sniffing, and negative scores for periods of inactivity. The data in this figure
show scores for 6 individual poly(I:C)-injected dams at the 3 time periods.
Effects of maternal immune stimulation on Toll-Like Receptors (TLR): We are also examining the
effects of poly(I:C) exposure during pregnancy on the expression and function of TLRs dur‐
ing fetal development and in neonates and adult offspring. TLRs are part of a larger family
of membrane bound cell surface and intracellular Pattern Recognition Receptors (PRR).
Eleven TLRs have been discovered in humans (TLRs 1-11), and 12 TLRs have been found in
mice (TLRs 1-12). First discovered in Drosophila [75], this family of molecules is very hetero‐
genous, complex, and highly conserved among species. Individual TLRs bind to particular
microbial products, such as LPS, peptidoglycan, lipoproteins, and flagellin on bacteria, as
well as viral fusion protein, unmethylated CpG motifs, double- and single-stranded RNAs
[76, 77]. TLR expression by cells of the innate and adaptive immune systems allows these
cells to recognize and respond to extracellular and intracellular microbial pathogens. Down‐
stream cell signaling pathways are initiated when ligands bind to TLRs, leading to activa‐
tion of different transcription factors (e.g., NF-κB and others), which stimulate expression of
pro-inflammatory cytokine genes (e.g., IL-1, IL-6, TNF, interferons).
Thus, TLRs play an early and important role at the interface between the environment and
host tissues by initiating immune responses against pathogens. In addition to expression on
cells of the innate and adaptive immune systems, TLRs are also expressed in/on many cell
types in various other tissues of the body, including the placenta, embryonic brain, and
hematopoietic progenitor cells. In the context of our experimental model of maternal im‐
mune stimulation during pregnancy, how the maternal response to poly(I:C) (a TLR3 ago‐
nist) during pregnancy affects the normal expression and function of TLR3, as well as other
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TLRs in the developing embryos and offspring is an important question that allows the de‐
sign of experiments that address underlying mechanisms.
Modulation and desensitization of TLR expression, as well as cross-talk among TLRs has
been shown in cells from humans and rodents. There is increasing evidence of TLR expres‐
sion during embryonic development in the placenta, fetal brain and hematopoietic stem
cells [78-81]. In this regard, we have obtained results indicating modulation of TLR expres‐
sion in 4wk old neonates from poly(I:C)-injected dams (Figure 7). Using pathway-focused
gene expression profiling qRT-PCR arrays, spleen cells from offspring of pregnant dams in‐
jected with the TLR3 agonist, poly(I:C), showed a 3.3 to 4.7 -fold increase in constitutive ex‐
pression levels of TLR2, 4 and 7 over those seen in age-matched control B6 offspring. In
contrast, expression levels of TLR3 and 9 were <2-fold greater than controls. These results
indicate that exposure to poly(I:C) (or poly(I:C)-induced cytokines) during fetal develop‐
ment results in altered TLR expression that persists after birth, consequences of which may
relate to differential immune responses to micro-organisms and auto-antigens. These data
also suggest that TLR modulation, desensitization, and cross-talk also occur when fetal tis‐
sues are exposed to TLR agonists in utero.
Figure 7. Altered constitutive expression of TLRs in offspring of poly(I:C)-injected dams. RNA was extracted di‐
rectly from unstimulated spleen cells of 4wk old offspring of poly(I:C)- and PBS-injected dams, and tested for expres‐
sion of TLRs using the RT2 Profiler PCR Array system. Data are expressed as fold-changes in gene expression for TLRs in
offspring of poly(I:C)-injected dams over PBS-injected dams. The results show >3-fold upregulation for TLR2, 4, and 7
and <2-fold increase for TLR3 and 9 in offspring of poly(I:C)- compared to PBS-injected dams.
Recent studies have shown expression of TLRs by neural progenitor cells (NPC), neurons
and glial cells in the adult brain, which may be important in the responses of these cells to
injury or infection [76, 82-88]. Studies of TLR expression in the developing rodent brain have
revealed that TLR3 appears as early as embryonic day 12.5 (E12.5) in mouse cortices, but de‐
clines over time. By contrast, TLR2 expression appears around E15.5 and increases with time
[70, 88]. Moreover, in standard in vitro neurosphere assays (used to assess developmental
potential of NPCs), both TLR2 and TLR3 activation appear to regulate NPC proliferation.
These studies raise questions regarding the expression of other TLRs during brain develop‐
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ment, and how that expression pattern is altered when dams are exposed to TLR agonists,
such as poly(I:C), during pregnancy. The structural and/or functional abnormalities seen in
the brains of offspring from poly(I:C)-injected pregnant dams may correlate with alterations
of the normal patterns of TLR expression in the developing brain. Therefore, disruption of
the normal TLR expression pattern might be involved in the observed structural and/or
functional changes in the brain of individuals with neurodevelopmental disorders, such as
schizophrenia and autism.
Cell Marker Percent Positive Cells in Fetuses from
PBS-injected dams poly(I:C)-injected dams
#1 #2 #1 #2
Sca-1+, c-kit+ (HSC) 0.3 0.3 1.5 1.3
Sca-1-, c-kit+ (CMP) 24.0 25.9 21.6 24.5
Sca-1+, c-kit- (CLP) 9.6 8.0 23.1 23.1
Pregnant dams were injected at E12 and fetuses were obtained 24 hrs later. Fetal liver cells from individual fetuses
were analyzed by FACS for expression of markers that define HSCs and early common progenitor cells.
Table 3. Hematopoietic Stem Cells in Fetal Liver
TLR expression on hematopoietic stem cells (HSCs): As previously mentioned, maternal expo‐
sure to poly(I:C) during pregnancy induces production of pro-inflammatory cytokines, in‐
cluding significant increases in IL-6 in maternal circulation, amniotic fluid, placenta, and
fetal brain [51, 89-93]. Direct injection of IL-6 to pregnant dams also results in consequences
for the offspring, including structural abnormalities in the brain, as well as behavioral and
cognitive abnormalities [30, 34-36, 38]. However, IL-6 also affects the immune system; it is
an autocrine growth factor for thymic epithelial cells [94], stimulates fetal hematopoiesis
[95], and can alter the balance of Tregs and Th17 cells towards the pro-inflammatory Th17
phenotype [96-101]. Thus, IL-6 is a key player in the differentiation of cells in the immune
system, and may play a role in the immune dysregulation seen in ASD.
Recent studies have also revealed that HSCs not only respond to cytokine signaling to ini‐
tiate myelopoiesis and lymphopoiesis, but also can sense microbial pathogens directly via
TLR signaling [78]. Administration of nanomolar concentrations of the TLR4 agonist, LPS,
triggers emigration of monocytes from the BM into the bloodstream, indicating that circulat‐
ing levels of TLR ligands can also stimulate HSCs within hematopoietic tissues [102]. Addi‐
tionally, treatment of mice with TLR3 agonist poly(I:C) activates HSCs to proliferate [103].
Therefore, it is likely that in the prenatal model we are studying, HSCs are influenced not
only by the poly(I:C) induced cytokines elicited during pregnancy, but also by this TLR3 ag‐
onist as well. Therefore, we have examined placentas, fetal livers, and neonatal bone mar‐
row from poly(I:C)-injected (vs.PBS-injected) pregnant dams and offspring to characterize
the changes in HSCs, as well as lineage-specific progenitor cells. We examined cells from
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these tissues for surface markers (Sca-1 and c-kit) that define HSCs, and the lineage-specific
progenitors for T cells (TCR, CD3), B cells (sIg, CD19), and myeloid cells (CD11b, CD11c).
An example of our results for HSCs in fetal liver is presented in Table 3. Pregnant dams were
injected at E12 with either PBS or poly(I:C), and fetuses were examined 24 hrs later. The data
show that in comparison to fetuses from PBS-injected dams, fetal livers from poly(I:C)-injected
dams had a 4- to 5-fold increase in the percentage of HSCs that were double-positive for Sca-1
and c-kit, and almost a 3-fold increase in the percentage of HSCs that expressed only Sca-1,
which are early Common Lymphoid Progenitors (CLP). By contrast, the percent of HSCs that
expressed only c-kit, which are early Common Myeloid Progenitors (CMP), was similar in all
fetal livers. These results are intriguing because they indicate hyper-proliferation of HSCs and
early CLP, which may forecast the preferential changes we have observed in mature T lympho‐
cytes in the adult offspring of poly(I:C)-injected dams [43-45, 60].
3. In vivo proof-of-concept experiments
In addition to our investigation of the consequences of maternal immune stimulation to preg‐
nant dams, embryonic tissues, and 2-4 wk old neonates, we have also extended our studies to
adult offspring of poly(I:C)-injected (vs. PBS-injected). Our guiding hypothesis is that as a re‐
sult of in utero exposure of the fetus to cytokines elicited by maternal immune stimulation (act‐
ing as a “first hit”), developmental programming of the immune system occurs in offspring,
which persists postnatally and into adulthood. In the case of this prenatal model, such fetal
programming results in development of a “pro-inflammatory” phenotype, such that upon
subsequent postnatal  exposure to an immune stimulus (i.e.,  second hit)  the offspring of
poly(I:C)-injected pregnant dams exhibit exacerbated responses in comparison to offspring of
PBS-injected dams. Such a scenario is also consistent with the “multiple hit” concept of mental
disorders [104, 105]. In the context of ASD, this would mean that abnormalities of behavior and
immune dysregulation in some children with ASD could reflect such developmental program‐
ming during embryonic development that is manifested postnatally upon encounter with a
second hit to their immune system. We tested this hypothesis by using adult offspring of
poly(I:C)-injected (vs. PBS-injected) pregnant dams in selected in vivo experimental models
that involve activation of their innate and/or adaptive immune systems.
Inflammatory response to TLR2 agonist, zymosan: We induced an antigen non-specific acute in‐
flammatory response in the peritoneal cavity with zymosan (TLR-2 agonist), and assessed
the qualitative and quantitative nature of the inflammatory response 4 hrs later [106].
Adult offspring from immunologically naïve poly(I:C)-injected dams were injected i.p. with
PBS (control) or zymosan. Adult offspring from immunologically naïve PBS-injected dams
were also injected with PBS or zymosan for comparison. Mice were euthanized at 4 hrs, and
2ml of cold PBS was used to flush their peritoneal contents. The number and type of perito‐
neal exudate cells were determined by manual counting and FACS analysis, and the perito‐
neal fluid was analyzed for the presence of cytokines.
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As shown in Table 4, the >2 fold increase in total Peritoneal Exudate Cell (PEC) count in the
zymosan-injected poly(I:C) offspring was significantly higher than the count recovered from
zymosan-injected PBS offspring. In contrast, there were no significant differences in absolute
PEC numbers in control PBS-injected adult poly(I:C) or PBS offspring. The peritoneal cellu‐
lar infiltrate in offspring injected with PBS was primarily mononuclear cells (monocytes and
lymphocytes) (Figure 8A). In contrast, the acute cellular inflammatory response in the peri‐
toneal cavity of zymosan-injected offspring was mostly neutrophils (Figure 8B).
Offspring
Total PEC
(x106)
Neutrophils IL-6 (pg/ml)
From Injected with Percent Absolutenumber (x106) Sera Peritoneal Fluid
PBS-injected dams PBS 0.8 ± 0.3 <5.0 <0.004 4 ± 0.6 15 ± 7.9
Zymosan 6.3 ± 1.8 70.0 ± 10 4.40 ± 1.9 420 ± 200 1176 ± 586
Poly(I:C)-injected
dams
PBS 1.0 ± 0.4 <5.0 <0.005 8 ± 2.7 6 ± 2.5
Zymosan 13.3 ± 2.1** 81.0 ± 6 10.8 ± 2.0** 2692 ± 514* 7808 ± 1306*
Adult offspring from immunologically naïve poly(I:C)-injected dams were injected i.p. with PBS (control) or zymosan.
Adult offspring from immunologically naïve PBS-injected dams were also injected with PBS or zymosan for compari‐
son. Mice were euthanized at 4 hrs, and 2ml of cold PBS was used to flush their peritoneal contents. The number and
type of peritoneal exudate cells (PEC) were determined by manual counting and FACS analysis, and sera and perito‐
neal fluids were analyzed for the presence of cytokines. N = 5-8, ** P=0.016 (student’s t-test). *P< 0.05 (student’s t-
test)
Table 4. Zymosan-induced acute inflammatory responses in offspring
Figure 8. Acute inflammatory response in zymosan-injected adult offspring. Adult offspring from poly(I:C)-inject‐
ed non-immune dams were injected i.p. with 1 ml of zymosan suspension or PBS (control). Four hours after injection,
peritoneal cavities were flushed with ice cold PBS. Cytospin slides were made from peritoneal exudate cells, and
stained with Wright’s/Giemsa stain. (A) PBS-injected offspring from poly(I:C)-injected non-immune dams at 630X. (B)
zymosan-injected offspring from poly(I:C)-injected non-immune dams at 630X.
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The percentage of neutrophils in zymosan-injected offspring from PBS-injected and poly(I:C)-
injected offspring (Table 4) were similarly high (i.e., 70% and 81%, respectively). However, be‐
cause the total number of PEC recovered from zymosan-injected offspring from poly(I:C)-
injected (vs. PBS-injected) dams was significantly higher, the absolute number of neutrophils
from zymosan-injected offspring was also significantly greater in offspring from poly(I:C)-in‐
jected dams. Given the huge infiltration of neutrophils into the peritoneal cavity in zymosan-
injected offspring, we also examined the bone marrow for evidence of increased myeloid
activity, and found evidence of increased myeloid activity in mice showing PEC counts in ex‐
cess of 10 x 106 cells. As also shown in Table 4, significantly higher levels of IL-6 were observed
in fluid obtained from the peritoneal cavity of zymosan-injected poly(I:C) offspring vs. PBS off‐
spring at 4 hrs after zymosan injection. Although not shown in the table, levels of TNF-α and
IL-10 were also significantly higher in these zymosan-injected poly(I:C) offspring.
Results from the myocardial Ischemia/reperfusion model: Based on the results we obtained using
injection of zymosan to mimic the acute inflammatory response induced by an infectious or‐
ganism, we wished to determine if the offspring of immunologically naïve poly(I:C)-injected
dams would also mount a more robust inflammatory responses to endogenous molecules
created by non-infectious tissue injury. The persistent neuroinflammation observed in
brains of individuals with autism and in rodents from experimental models of neurodeve‐
lopmental disorders may be triggered by such endogenous stimuli. For these experiments,
we selected a well-characterized cardiac model in which ischemia/reperfusion causes a
“sterile” inflammatory response. After an acute myocardial infarction, reperfusion (by
thrombolytic therapy or primary percutaneous intervention) is currently the most effective
strategy to minimize myocardial damage and improve clinical outcome [107]. Paradoxically,
restoring blood flow to the ischemic heart tissue can also induce injury – a phenomenon
called myocardial reperfusion injury (R/I). The modes of myocardial cell injury and death
following myocardial R/I are apoptosis, autophagy, and necrosis, and several underlying
mechanisms have been identified or proposed [108-112]. However, one well-studied cause
of myocardial R/I is the host inflammatory response that occurs during reperfusion. Despite
the fact that ischemia and reperfusion takes place in a sterile environment, activation of in‐
nate and adaptive immune responses occurs and contributes to injury (reviewed in [112]).
Contributing factors of reperfusion-induced inflammation include activation of Toll-like Re‐
ceptors (TLRs), complement activation, free radical generation, cytokine cascade initiated by
release of pro-inflammatory cytokines, and chemokine upregulation [113-116]. The presence
of these immune mediators leads to recruitment of neutrophils to the ischemic myocardium,
which exert cytotoxic effects themselves by release of proteolytic enzymes. Another paradox
of myocardial reperfusion is that it may also significantly enhance a healing process. Studies
have shown that Monocyte Chemoattractant Protein-1 (MCP-1) is also induced in the in‐
farcted area, which may regulate myeloid cell recruitment, leading to accumulation of mac‐
rophages and mast cells that secrete angiogenesis-stimulating factors, which facilitate
myocardial repair [117, 118].
For these experiments, adult offspring of immunologically naïve poly(I:C)-injected and PBS-
injected dams were anesthetized, intubated and ventilated; the heart was exposed by a thor‐
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acotomy through the 4th and 5th ribs, and a suture was passed under the left coronary
artery. The left coronary artery was occluded for a period of 20 min, and reperfusion applied
for 24 hrs. Reperfusion was achieved by removal of the occlusion, the thoracotomy incision
was closed, and mice were allowed to recover under monitoring in an incubator. After 24 hr
of reperfusion, mice were assessed for cardiac injury as previously described [119, 120].
As shown in Figure 9, significantly greater cardiac damage was observed in offspring from
immunologically naïve poly(I:C)-injected dams than in offspring from control PBS-injected
dams. We are currently assessing the underlying mechanisms responsible for the difference
in levels of damage in experimental and control offspring. Myocardial I/R induces infiltra‐
tion of inflammatory cells, such as neutrophils that secrete cytokines/chemokines, including
IL-6 and TNFα, which in turn contribute to cell death, fibrosis and reduced myocardial con‐
tractility [121]. Therefore, it is likely that similar underlying inflammatory mechanisms also
occur in the myocardial I/R model as those described above for the acute inflammation in‐
duced by zymosan. In the zymosan and myocardial I/R models, the response is measured
within hours of the immune stimulus. This indicates that elements of the innate immune
system are the primary mediators of the pathology, and suggest that modification of these
components has occurred as a result of maternal immune stimulation during pregnancy.
Figure 9. Cardiac damage in offspring of poly(I:C)-injected vs. PBS-injected immunologically naïve pregnant
dams. Adult offspring from poly(I:C)-injected (Exp) and PBS-injected (Control) dams were subjected to cardiac ische‐
mia (20 min) and reperfusion (24 hrs), and assessed for cardiac damage (indicated by infarct size). Offspring from
poly(I:C)-injected dams exhibited significantly greater cardiac damage (p=0.011; student’s t-test) than control off‐
spring. (N = 8 mice/group; 8 weeks of age)
Response to auto-antigens: In order determine if components of the adaptive immune system al‐
so mount more robust responses following immune stimulation we chose a well-characterized
EAE model of an immune-mediated disease, and used adult offspring of pregnant dams with
immunological memory. We have previously shown that T cells from offspring of poly(I:C)-in‐
jected pregnant dams with immunological memory (i.e., immune) preferentially differentiate
to become Th17 cells after in vitro activation [43-45, 60]. In contrast, T cells from offspring of
poly(I:C)-injected immunologically naïve pregnant dams (i.e., non-immune) do not show such
Th17 cell preferential differentiation. Th17 cells have been shown to be involved in the neuro‐
pathology responsible for the clinical symptoms that develop in Experimental Autoimmune
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Encephalomyelitis (EAE), a mouse model of multiple sclerosis [122-128]. Female offspring of
poly(I:C) (vs. PBS) -injected pregnant dams were injected s.c. in each hind flank with an ence‐
phalogenic-peptide (MOG35-55) in Complete Freund ’s adjuvant (CFA). I.p. injections of pertus‐
sis toxin were given after MOG immunization to enhance the immune response and promote T
cell migration into the brain [129]. Typically, 10 – 12 days after injection of MOG and pertussis,
90% of B6 mice develop progressively: weakness and paralysis in their tail, hindlimb paresis
and finally hindlimb paralysis. Controls that receive CFA and pertussis toxin, but no MOG, do
not develop clinical signs of EAE.
However, offspring of poly(I:C)-injected immune pregnant dams exhibited clinical signs of
EAE significantly earlier and with higher frequency than offspring of poly(I:C)-injected non-
immune dams (Figure 10). More than 70% of poly(I:C) immune offspring began to show
clinical signs of EAE by day 4 after MOG35-55 immunization compared to none seen in
poly(I:C) non-immune offspring. On day 7 after immunization, 25% of poly(I:C) non-im‐
mune offspring began to show symptoms, but this was still significantly lower than the
>70% seen in poly(I:C) immune offspring. By day 9, >60% of poly(I:C) non-immune off‐
spring showed clinical signs of EAE. In addition to the higher frequency of clinical signs of
EAE, poly(I:C) immune offspring also had significantly higher disease severity from days
4-7 post MOG35-55 immunization compared to poly(I:C) non-immune offspring [45, 60]. From
days 9-20, the development of EAE among offspring was very similar in both groups. How‐
ever, the earlier appearance of clinical symptoms affords a window of opportunity to inves‐
tigate underlying mechanisms in the EAE model that can be applied in future studies of
mechanisms of neuroinflammation and pathogenesis in experimental models of autism.
Figure 10. Frequency of mice showing clinical signs of EAE. Adult offspring of of poly(I:C)-injected dams with im‐
munological memory [vs. immunologically naïve poly(I:C)-injected dams] were injected s.c. with MOG in CFA and i.p.
with pertussis toxin. Mice were scored for clinical signs of neurological impairment, and the percent of mice showing
clinical signs at the indicated times after immunization is shown in this figure.
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These results are consistent with our hypothesis of fetal programming due to effects of ma‐
ternal immune stimulation during pregnancy, leading to increased susceptibility of off‐
spring to a “second hit” postnatal stimulus. This is likely due to an overall heightened
immune responsiveness to develop EAE by MOG-specific Th cells that preferentially differ‐
entiate to become Th17 cells in these pro-inflammatory mice and/or a lower antigen thresh‐
old for initiation of an immune response. Another contributing factor could be differential
responses of these pro-inflammatory offspring to TLR agonists on the mycobacteria in CFA
(TLR2) and pertussis toxin (TLR4) used as part of the MOG immunization protocol [130,
131]. Support for this possibility is shown in Figure 7, where offspring of poly(I:C)-injected
dams who possess immunological memory showed >3-fold higher expression of TLR2 and
TLR4 compared to controls.
Overall, our results are consistent with the concept of developmental programming of the
immune system [71, 132-136]. These changes persist into adulthood, and increase the vulner‐
ability of offspring from poly(I:C)-injected dams to develop immune-mediated diseases
when exposed to subsequent antigen specific, as well as antigen non-specific immune chal‐
lenges. There is considerable plasticity of the developing immune system, and maternal
stressors, such as immune stimulation during pregnancy, can modulate normal develop‐
ment [137]. Immune stimuli during the perinatal period of life can also act as a vulnerability
factor for later-life alterations of immune responsiveness [132]. Such fetal programming has
been described in relation to abnormalities of metabolism, growth, and behavior in offspring
[138-140], as well as in relation to allergic and autoimmune disorders [133-135, 141-143]. The
fetal programming of the developing immune system in this prenatal mouse model descri‐
bed herein is most likely mediated by cytokines and/or other inflammatory mediators pro‐
duced by immune stimulation in response to poly(I:C) given to the pregnant dam. However,
as we have previously shown, the sources of these products of immune stimulation are of
both maternal and fetal origin [44].
4. Summary and conclusions
The results from our investigation of the poly(I:C)-induced prenatal model of neurodeve‐
lopmental  disorders  further  identifies  and  characterizes  gene-environment  interactions
(i.e.,  maternal  immune  response  genes  vs.  environmental  antigens)  that  influence  fetal
development in ways that have consequences for health and disease of offspring. Further
characterization  of  this  model  presents  excellent  opportunities  to  define  the  underlying
mechanisms responsible for the alterations that occur during embryological development,
which persist and are manifested in adult offspring. We are using this model to examine
the peripheral  immune system of  offspring to identify mechanisms that  explain the im‐
mune dysregulation that is characteristic in a significant cohort of children with Autism
Spectrum  Disorders  (ASD).  The  immunological  changes  we  find  in  offspring  of  dams
that receive immune stimulation during pregnancy involve significant differences in cyto‐
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kines and T helper (Th) lymphocyte subsets.  Our investigation of this mouse model has
also provided a scientific basis for an ongoing translational research project to determine
if  similar molecular pathogenic mechanisms are involved in the cohort  of  ASD children
who also exhibit evidence of immune dysregulation. Thus, mothers of autistic children in
this cohort  have polymorphisms in the same cytokine genes that  promote inflammatory
reactions  in  our  mouse  model,  and  their  children  with  autism and immune dysregula‐
tion inherit the maternal pro-inflammatory phenotype.
Convincing  evidence  from  this  model  has  shown  that  pro-inflammatory  cytokines  pro‐
duced by maternal  immune stimulation during pregnancy induce changes in the devel‐
opment  of  the  immune  system  and  brain  of  offspring  that  result  in  similar
immunological  and  behavioral  manifestations  as  those  seen  in  individuals  with  ASD.
Therefore,  our results are relevant to the concept of developmental programming of the
immune system.  In  utero  exposure  to  these  cytokines  produces  offspring  that  exhibit  a
pro-inflammatory  phenotype,  which  persists  throughout  the  neonatal  period  and  into
adulthood.  Subsequently,  upon postnatal  exposure  to  agents  that  stimulate  the  immune
system, offspring that exhibit  this phenotype mount a more robust immune response in
which  pro-inflammatory  immune  elements  (i.e.,  Th17  cells  and  cytokines)  predominate.
Th17  cells  have  been  shown  to  mediate  immunopathology  in  numerous  disorders  that
model human diseases,  such as multiple sclerosis,  arthritis,  inflammatory bowel disease,
atherosclerosis,  and diabetes.  Our use of  offspring that  have Th cells  with the potential
to preferentially differentiate into Th17 cells will also determine the contribution of Th17
cells to the etiology and pathogenesis of ASD.
The nature and timing of this second hit to the immune system may also be a critical de‐
termining factor in the manifestation of immune outcomes. Thus, if  immune stimulation
occurs  very early  in  life  when organ systems,  such as  the  brain,  are  still  developing,  it
may lead to neurodevelopmental disorders like ASD. Contrastingly, if the second hit oc‐
curs later in life, the outcome may be manifested as an autoimmune disorder. However,
possession of a pro-inflammatory phenotype as described in our model is not necessarily
a disadvantage. In certain clinical scenarios, such as malignancy or infection with patho‐
genic  micro-organisms,  a  more  robust  immune  response  may  provide  survival  advant‐
age.  Indeed,  our preliminary results  in an infection model indicate that  the offspring of
poly(I:C)-injected  pregnant  dams  that  exhibit  a  pro-inflammatory  phenotype  show  in‐
creased survival time and lower pathogen burden than control offspring from PBS-inject‐
ed pregnant dams.
As with many other components of the immune system, the effector functions resulting
from developmental programming induced by maternal immune stimulation during preg‐
nancy have the potential to be a double-edged sword with outcomes that can be either detri‐
mental or beneficial. The future challenge in studying this prenatal model system will be to
sufficiently understand the underlying cellular and molecular mechanisms to enable the de‐
sign of effective therapeutic interventions to inhibit outcomes that are harmful, and enhance
those that are beneficial.
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